177264-20-9

Upstream product

• 133052-28-5 2-butyl-4,5-dihydro-4-oxo-3H-imidazo<4,5-c>pyridine 
• 159547-21-4 [3-Fluoro-2'-(N-t-butylsulfamoyl)biphenyl-4-yl]methyl Bromide 

Downstream Products

• 193753-08-1 2-butyl-3-{[3-fluoro-(2'-tert-butylaminosulfonyl)-4-biphenylyl]methyl}-4,5-dihydro-5-[(2-oxo-2-piperidino)ethyl]-3H-imidazo[4,5-c]pyridin-4-one 
• 1027145-73-8 4'-[2-Butyl-4-oxo-5-(2-oxo-2-piperidin-1-yl-ethyl)-4,5-dihydro-imidazo[4,5-c]pyridin-3-ylmethyl]-3'-fluoro-biphenyl-2-sulfonic acid amide 
• 193753-07-0 N-Benzyl-2-[2-butyl-3-(2'-tert-butylsulfamoyl-3-fluoro-biphenyl-4-ylmethyl)-4-oxo-3,4-dihydro-imidazo[4,5-c]pyridin-5-yl]-acetamide 
• 193752-98-6 4'-[2-Butyl-4-oxo-5-(2-oxo-2-phenyl-ethyl)-4,5-dihydro-imidazo[4,5-c]pyridin-3-ylmethyl]-3'-fluoro-biphenyl-2-sulfonic acid tert-butylamide 
• 193753-06-9 N-tert-Butyl-2-[2-butyl-3-(2'-tert-butylsulfamoyl-3-fluoro-biphenyl-4-ylmethyl)-4-oxo-3,4-dihydro-imidazo[4,5-c]pyridin-5-yl]-acetamide 
• 193753-04-7 2-[2-Butyl-3-(2'-tert-butylsulfamoyl-3-fluoro-biphenyl-4-ylmethyl)-4-oxo-3,4-dihydro-imidazo[4,5-c]pyridin-5-yl]-N-isobutyl-acetamide 
• 193753-09-2 2-[2-Butyl-3-(2'-tert-butylsulfamoyl-3-fluoro-biphenyl-4-ylmethyl)-4-oxo-3,4-dihydro-imidazo[4,5-c]pyridin-5-yl]-N,N-diethyl-acetamide 
• 193752-99-7 4'-[2-Butyl-4-oxo-5-(3-oxo-3-phenyl-propyl)-4,5-dihydro-imidazo[4,5-c]pyridin-3-ylmethyl]-3'-fluoro-biphenyl-2-sulfonic acid tert-butylamide 

Relevant academic research and scientific papers

Novel 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridines. Potent angiotensin II receptor antagonists with high affinity for both the AT1 and AT2 subtypes

The synthesis and pharmacological activity of balanced high affinity non-peptide angiotensin II antagonists of the AT1 and AT2 subtype receptors have been presented. A series of previously prepared AT1 selective 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridines were modified at four different positions in order to increase the AT2 binding affinity by maintaining the nanomolar activity for the AT1 receptor. The targeted AT2/AT1 IC50 binding ratio of ~ 1 was achieved with a number of compounds possessing a small alkyl chain at C-2, different acetamide groups at N-5 and a 3-fluoro and 2'-carboxamidosulfonyl substituent at the biphenylmethyl moiety. These modifications led to analogue 12s, which exhibited an AT2/AT1 ratio of 0.74, a subnanomolar AT1 antagonistic potency (0.18 nM) and a high metabolic stability in rat and monkey liver microsomes in vitro. After oral administration of 3 mg/kg to cynomolgus monkeys, EMD 90423 (potassium salt of 12s) demonstrated good efficacy and a long duration of action as an antihypertensive agent.